Sandoz launches generic cyclophosphamide injection

PRINCETON, N.J. — Sandoz last week announced the launch of a generic version of cyclophosphamide injection, USP. Sandoz is launching the drug through collaboration with Jiangsu Hengrui Medicine Co., which owns the product's abbreviated new drug application. 

 

Cyclophosphamide for injection, USP, is a chemotherapy agent used to treat certain types of cancer in adults and pediatric patients. It also is used in selected cases of biopsy proven “minimal change” nephrotic syndrome in children, according to the company.

 

“We are pleased to add cyclophosphamide injection to our strong and growing portfolio of generic oncology injectables,” said Peter Goldschmidt, president of Sandoz. “Collaborations with pharmaceutical companies are an important aspect of our strategy of being first-to-market with key affordable, high-quality treatment options.” 

 

U.S. sales for cyclophosphamide injection were $420 million for the 12 months ending September 2014, according to IMS Health data. Sandoz will market the drug in 500-mg, 1-g and 2-g single-dose vials.